FilingReader Intelligence
Hebang Biotechnology reports 73% profit drop in H1
August 19, 2025 at 05:13 PM UTC•By FilingReader AI
Hebang Biotechnology reported H1 2025 revenue of 3.92 billion yuan, down 19%, and net profit of 51.77 million yuan, a 73% decrease year-on-year, primarily due to market changes.
The company has converted 114,500 shares from its convertible bond, with 417.09 million yuan of the 4.58 billion yuan raised applied to projects.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
Hebang Bioscience 2025 semi-annual report summaryAugust 19, 2025 at 08:00 AM UTC
Hechengbono Biotechnology Co., Ltd. 2025 semi-annual announcement of key operating dataAugust 19, 2025 at 08:00 AM UTC
Walson Biology's special report on the deposit and actual use of raised funds for the first half of 2025August 19, 2025 at 08:00 AM UTC
Announcement of resolutions from the twenty-fifth meeting of the sixth board of directors of Hebang BiologyAugust 19, 2025 at 08:00 AM UTC
SSE:603077•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Sichuan Hebang Biotechnology publishes news
Free account required • Unsubscribe anytime